| Home Market Dynamics You and Market Sector Analysis Company Insights AI Investing About Contact Us Login |
| The price action of Health Care (XLV) sector is shaped by numerous forces, ranging from broad macroeconomic trends to company-specific performance and market structure. The overall sentiment for Health Care sector is very positive (overall 6, positive 6, negative 0) on 20251125. The forces of Valuation Sentiment (3.5), Sentiment towards Fundamentals (2.9), Price Level (2), Sector Price Trend (1.6), Option Speculation (1.5), Broad Market Trend (0.5), and Market Risk Prefrence (0) will drive up the price. The forces of and Market Risk Prefrence (0) will drive down the price. 'Buy the dips' is the preferred trading strategy. Hourly SMA 20 trend line is likely to provide a support from any pullbacks. The swing to upside will be significant considering the high positive sentiment forces (6). The extreme bullish overall sentiment (6) may signal the top of this uptrend. The sentiment for Broad Market Trend is calculated based on SPY trend. The sentiment for Sector Price Trend is calculated based on XLV trend. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Prefrence is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. |
| Date | Attention | Average Attention | Price | Price Level | Change | SMA10 Trend | Market Sentiment | Trend Sentiment | Fundamentals | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-25 | 1% | 1.7% | 158.76 | 103 | 2.26% | 0.52% | 4.3 | 1.6 | 2.9 | 6.1 |
| 2025-11-24 | 3% | 1.9% | 155.25 | 91 | 0.38% | 0.53% | 4.4 | 1.1 | 3.2 | 0.2 |
| 2025-11-23 | 1% | 1.7% | 3.5 | 1 | 2.7 | -7 | ||||
| 2025-11-22 | 1% | 1.6% | 3.4 | 1 | 2.6 | 8.5 | ||||
| 2025-11-21 | 3% | 1.6% | 154.66 | 93 | 2.17% | 0.53% | 3.3 | 1 | 2.7 | 7.1 |
| 2025-11-20 | 2% | 1.6% | 151.38 | 75 | -0.62% | 0.4% | 2 | -0.2 | 2.3 | 6.3 |
| 2025-11-19 | 1% | 1.4% | 152.32 | 84 | -0.17% | 0.47% | 1.9 | 0.5 | 2.2 | 2.7 |
| 2025-11-18 | 2% | 1.4% | 152.58 | 90 | 0.56% | 0.47% | 2 | 1 | 1.8 | 2.3 |
| 2025-11-17 | 2% | 1.3% | 151.74 | 89 | -0.09% | 0.47% | 2.1 | 1.1 | 1.6 | 1.6 |
| 2025-11-16 | 0% | 1.1% | 2.9 | 1.5 | 2 | 5 | ||||
| Both emotion scores and sentiment scores are calculated in a -10 - +10 scale. | The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| 1 (5) This organ transport stock is breaking out. Where it might go, according to the charts Todd Gordon goes through the technicals of the health care sector and this organ transport stock. (https://www.cnbc.com/) Tue. Nov 25, 2025 | |
| 2 (4) Why Novo Nordisk Stock Keeps Getting Punished For Headlines That Don't Matter Novo Nordisk is undervalued and oversold, despite strong fundamentals and a promising pipeline. The market's reaction to headlines. (https://www.benzinga.com/) Tue. Nov 25, 2025 | |
| 3 (7) Small Caps, Pharma Surge As AI Rotation Broadens, Nvidia Tumbles: What's Moving Markets Tuesday? Wall Street's sector rotation entered full throttle Tuesday, with investors pouring into previously overlooked corners of the market amid an AI-driven shift that now favors undervalued small caps and defensive names such as health care. (https://www.benzinga.com/) Tue. Nov 25, 2025 | |
| 4 (8) Merck, Home Depot share gains contribute to Dow's 519-point rally Shares of Merck and Home Depot are trading higher Tuesday afternoon, propelling the Dow Jones Industrial Average rally. The Dow Dow Jones Industrial Average is trading 519 points (1.1%) higher, as shares of Merck Merck & Co. Inc. and Home Depot Home Depot Inc. have contributed to the index's intraday rally. (https://www.marketwatch.com/) Tue. Nov 25, 2025 | |
| 5 (7) Dow up 400 points on gains for Merck, Nike stocks Powered by positive growth for shares of Merck and Nike, the Dow Jones Industrial Average is trading up Tuesday morning. The Dow Dow Jones Industrial Average is trading 402 points higher (0.9%), as shares of Merck Merck & Co. Inc. and Nike Nike Inc. Cl B have contributed to the blue-chip gauge's intraday rally. (https://www.marketwatch.com/) Tue. Nov 25, 2025 | |
| 6 (6) Novo Nordisk’s weight-loss-drug trial provides rare good news in a rocky year Novo Nordisk, whose shares have stumbled this year, on Tuesday announced a positive trial result for a weight-loss drug in development. (https://www.marketwatch.com/) Tue. Nov 25, 2025 | |
| 7 (6) Novo Nordisk’s weight-loss-drug trial provides rare good news in a rocky year Novo Nordisk, whose shares have stumbled this year, on Tuesday announced a positive trial result for a weight-loss drug in development. (https://www.marketwatch.com/) Tue. Nov 25, 2025 | |
| 8 (-6) Novo Nordisk Faces Setback. Here's What Caused the Ozempic Maker's Stock to Tumble Monday. Novo Nordisk shares tumbled Monday morning after the Danish drugmaker posted the latest results from a drug trial. (https://www.investopedia.com/) Mon. Nov 24, 2025 | |
| 9 (8) Agilent beats quarterly revenue estimates on strong demand for lab tools () -Life sciences firm Agilent Technologies on Monday beat fourth-quarter revenue estimates, helped by strong demand for medical tools and equipment used in lab research and diagnostic services. The laboratory equipment maker also forecast revenue for financial year 2026, which started in November, slightly ahead of Wall Street expectations. (https://finance.yahoo.com/) Mon. Nov 24, 2025 | |
| 10 (0) Stocks making the biggest moves midday: Novo Nordisk, Inspire Medical, Tesla, Tegna, Oscar Health and more These are some of the stocks posting the largest midday moves. (https://www.cnbc.com/) Mon. Nov 24, 2025 | |
| 11 (6) Bayer Stroke Drug Hits Trial Goals, Analyst Sees Positive Data Readout From Bristol Myers' Milvexian After Failed Study Bayer's asundexian cut ischemic stroke risk without more bleeding, boosting FXIa optimism while raising fresh questions for Bristol Myers' milvexian program. (https://www.benzinga.com/) Mon. Nov 24, 2025 | |
| 12 (5) Should You Buy Shares of UnitedHealth in November? A famous investor recently bought shares of UnitedHealth. (https://www.fool.com/) Mon. Nov 24, 2025 | |
| 13 (-4) Novo Nordisk’s Ozempic Pill Fails in Long-Shot Alzheimer’s Effort A pill version of Novo Nordisk A/S’s Ozempic failed to slow the progression of Alzheimer’s disease in a pair of long-shot studies that aimed to open up a new use for blockbuster obesity drugs. (https://www.bloomberg.com/) Mon. Nov 24, 2025 | |
| 14 (-7) Novo Nordisk stumbles against Eli Lilly in GLP-1drug battle. Which stock is the best buy from here? Eli Lilly's stock is soaring while Novo Nordisk is sinking. Why it makes sense to stick with the market winner, despite its rising valuation. (https://www.cnbc.com/) Mon. Nov 24, 2025 | |
| 15 (8) Health care just did something it hadn't done since late 1998. These names on our list stand to benefit the most An event this rare historically precedes big returns. (https://www.cnbc.com/) Mon. Nov 24, 2025 | |
| 16 (1) Republicans push Obamacare tax credit alternatives as enrollment deadline looms Republicans are proposing alternatives to Obamacare enhanced tax credits, with the enrollment deadline just three weeks away. (https://www.cnbc.com/) Mon. Nov 24, 2025 | |
| 17 (7) Stock Market Today: Dow, Nasdaq Up As Alphabet, Tesla Jump; These Health Plays Test Entries (Live Coverage) The Dow Jones index and the Nasdaq rose on the stock market today, with Tesla and Alphabet among AI stocks jumping. Health stocks tested entries. (https://finance.yahoo.com/) Mon. Nov 24, 2025 | |
| 18 (-5) Novo's GLP-1 fails Alzheimer's trial goals, Tegna stock falls Yahoo Finance anchor Julie Hyman tracks Monday's top moving stocks and biggest market stories in this Market Minute. Bitcoin (BTC-USD) is down about 30% from its peak, trading around $87,000. Shares of broadcast company Tegna (TGNA) are falling after President Trump said he was against the Federal Communications Commission (FCC) lifting its cap on local TV station ownership. Novo Nordisk (NVO) stock is under pressure after the company's GLP-1 failed its late-stage trial goals for treating Alzheimer's. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. (https://finance.yahoo.com/) Mon. Nov 24, 2025 | |
| 19 (3) Elon Musk hypes Tesla AI chips, Novo stock plunges on drug trial flop Morning Brief Host Julie Hyman tracks several of the day's top trending stock tickers, including Tesla (TSLA), Novo Nordisk (NVO), Oscar Health (OSCR), and Centene (CNC). To watch more expert insights and analysis on the latest market action, check out more Morning Brief. (https://finance.yahoo.com/) Mon. Nov 24, 2025 | |
| 20 (8) Health insurers rise on report Trump considering ACA subsidy extension health insurers jumped on Monday following a media report the White House was preparing to unveil a policy framework that would extend Affordable Care Act premium subsidies - also known as Obamacare - for two years and add new eligibility limits. Shares of Centene jumped about 7% and Molina Healthcare gained around 4%, while Elevance Health climbed more than 2% in early trading. (https://finance.yahoo.com/) Mon. Nov 24, 2025 | |
| 21 (-6) Novo Nordisk’s oral GLP-1 drug didn’t work on Alzheimer’s as hoped, and the stock tumbles Novo Nordisk’s stock tumbles after its oral GLP-1 drug failed to show much benefit over a placebo against Alzheimer’s. (https://www.marketwatch.com/) Mon. Nov 24, 2025 | |
| 22 (8) Dow up nearly 150 points on gains for Merck, Amazon.com Inc. stocks The Dow Jones Industrial Average is climbing Monday morning with shares of Merck and Amazon.com Inc. leading the way for the blue-chip average. Shares of Merck Merck & Co. Inc. and Amazon.com Inc. Amazon.com Inc. are contributing to the index's intraday rally, as the Dow Dow Jones Industrial Average is trading 142 points higher (0.3%). (https://www.marketwatch.com/) Mon. Nov 24, 2025 | |
| 23 (8) The 18 most promising startups in healthcare in 2025, according to investors We asked top investors at firms like A16z and Kleiner Perkins to name the healthcare startups they've been watching this year. Here are their picks. (https://www.businessinsider.com/) Mon. Nov 24, 2025 | |
| 24 (-8) Novo Nordisk Plunges After Ozempic Pill Fails Alzheimer's Trials - Shares Suffer Worst Year Ever ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero (https://www.zerohedge.com/) Mon. Nov 24, 2025 | |
| 25 (-8) Novo Nordisk Stock Plummets After Ozempic-Maker’s Alzheimer’s Drug Trial Fails The company said the weight loss and diabetes treatment drug failed to show any significant reduction in the progression of Alzheimer's disease in patients. (https://www.forbes.com/) Mon. Nov 24, 2025 | |
| 26 (-7) Novo Nordisk Alzheimer's drug trials fail in blow to weight-loss giant COPENHAGEN (Reuters) -Novo Nordisk's closely-watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the progression of the brain-wasting disease, the firm said on Monday, a blow to the obesity drug giant that sent its shares sliding. The trials, which Novo had previously called a "lottery ticket" to underline its highly uncertain outcome, were testing whether the medicine could slow cognitive decline in patients. (https://finance.yahoo.com/) Mon. Nov 24, 2025 | |
| 27 (-7) Novo Nordisk’s oral GLP-1 drug didn’t work on Alzheimer’s as hoped, and the stock tumbles Novo Nordisk’s stock tumbles after its oral GLP-1 drug failed to show much benefit over a placebo against Alzheimer’s. (https://www.marketwatch.com/) Mon. Nov 24, 2025 | |
| 28 (8) Bayer’s stock is jumping on a stroke drug trial — and so is Bristol Myers Squibb Bayer stock jumped on Monday after the German healthcare company said a late-stage stroke drug trial achieved its goals. (https://www.marketwatch.com/) Mon. Nov 24, 2025 | |
| 29 (-7) Novo Nordisk’s oral GLP-1 drug didn’t work on Alzheimer’s as hoped, and the stock tumbles Novo Nordisk’s stock tumbles after its oral GLP-1 drug failed to show much benefit over a placebo against Alzheimer’s. (https://www.marketwatch.com/) Mon. Nov 24, 2025 | |
About
Contact Us
Copyright ©2025 TheMarketUnfolds. All rights reserved. Denver, Colorado, USA